HUP0400683A2 - HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény - Google Patents

HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény

Info

Publication number
HUP0400683A2
HUP0400683A2 HU0400683A HUP0400683A HUP0400683A2 HU P0400683 A2 HUP0400683 A2 HU P0400683A2 HU 0400683 A HU0400683 A HU 0400683A HU P0400683 A HUP0400683 A HU P0400683A HU P0400683 A2 HUP0400683 A2 HU P0400683A2
Authority
HU
Hungary
Prior art keywords
inhibitor
her2
her2 inhibitor
group
particle size
Prior art date
Application number
HU0400683A
Other languages
English (en)
Inventor
Eiji Nara
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of HUP0400683A2 publication Critical patent/HUP0400683A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya egy körülbelül 3 mm vagy kisebb átlagosrészecskemérettel rendelkező HER2-inhibitor, továbbá körülbelül 3 mmvagy kisebb átlagos részecskemérettel rendelkező HER2-inhibitor vízbenvagy vizes oldatban diszpergálva. A találmány tárgya az előző HER2-inhibitort tartalmazó készítmény. A találmány tárgya eljárás a fentiHER2-inhibitor előállítására, amely szerint a HER2-inhibitort vízbenvagy vizes oldatban aprítják fel. A találmány szerinti körülbelül 3 mmvagy kisebb átlagos részecskemérettel rendelkező HER2-inhibitor vagyannak készítménye a HER2-inhibitor jelentősen jobb felszívódásiképességével rendelkezik. A fenti HER2-inhibitor, amely az (I)általános képletű vegyület, ahol a képletben R jelentése egy adottesetben helyettesített aromás heterociklusos csoport, X jelentéseoxigénatom, adott esetben oxidált kénatom, -C(=O)- vagy -CH(OH)-csoport, Y jelentése CH-csoport vagy N-atom, p jelentése 0-10 értékűegész szám, q jelentése 1-5 értékű egész szám, a (I/a) általánosképletű csoport jelentése adott esetben helyettesített aromásazolcsoport és az A-gyűrű tovább lehet helyettesítve, vagy annak sójavagy elővegyülete. Ó
HU0400683A 2000-12-11 2001-12-11 HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény HUP0400683A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375608 2000-12-11
PCT/JP2001/010827 WO2002048142A1 (fr) 2000-12-11 2001-12-11 Compositions medicamenteuses presentant une meilleure absorbabilite

Publications (1)

Publication Number Publication Date
HUP0400683A2 true HUP0400683A2 (hu) 2004-06-28

Family

ID=18844596

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400683A HUP0400683A2 (hu) 2000-12-11 2001-12-11 HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény

Country Status (10)

Country Link
US (1) US20040053972A1 (hu)
EP (1) EP1350793A1 (hu)
KR (1) KR20040025881A (hu)
CN (1) CN1487936A (hu)
AU (1) AU2002221115A1 (hu)
CA (1) CA2431322A1 (hu)
HU (1) HUP0400683A2 (hu)
NO (1) NO20032614L (hu)
PL (1) PL362172A1 (hu)
WO (1) WO2002048142A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984653B2 (en) 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
CN1882569B (zh) * 2003-09-19 2010-09-29 阿斯利康(瑞典)有限公司 喹唑啉衍生物
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
JP4639745B2 (ja) * 2004-01-19 2011-02-23 青葉化成株式会社 難固結性のタンパク質変性抑制剤粉末およびその使用方法
JP4982084B2 (ja) * 2004-02-09 2012-07-25 株式会社サンギ 抗腫瘍剤
TW200621240A (en) * 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1849830B1 (en) * 2005-01-28 2012-02-29 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
WO2006109635A1 (ja) * 2005-04-06 2006-10-19 Kabushiki Kaisha Sangi 腸管吸収用抗腫瘍剤
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US8088782B2 (en) * 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US7749300B2 (en) * 2008-06-05 2010-07-06 Xerox Corporation Photochemical synthesis of bimetallic core-shell nanoparticles
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
UA109109C2 (uk) * 2009-01-15 2015-07-27 Сефалон, Інк. Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
JP5944514B2 (ja) * 2011-10-14 2016-07-05 アレイ バイオファーマ、インコーポレイテッド 固体分散体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
EP0912562A1 (en) * 1996-07-19 1999-05-06 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
EP1350793A1 (en) 2003-10-08
CN1487936A (zh) 2004-04-07
US20040053972A1 (en) 2004-03-18
WO2002048142A1 (fr) 2002-06-20
PL362172A1 (en) 2004-10-18
KR20040025881A (ko) 2004-03-26
NO20032614D0 (no) 2003-06-10
AU2002221115A1 (en) 2002-06-24
CA2431322A1 (en) 2002-06-20
NO20032614L (no) 2003-08-05

Similar Documents

Publication Publication Date Title
HUP0400683A2 (hu) HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
HUP9800462A2 (hu) Aril-szulfonil-amino-hidroxámsav-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
AP1739A (en) Azaindoles
RS20050469A (en) Pyrrolopyrimidine derivatives
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
ES2193874A1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
JO2339B1 (en) Benzamidazole compounds
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
RU2008142261A (ru) Фармацевтическая композиция с модифицированным высвобождением и ее применение
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
MY141869A (en) Mouth rinse compositions
GB0314967D0 (en) Piperazine derivatives
MY150070A (en) Pharmaceutically active compounds, their manufacture, compositions containing them and their use
ES8506621A1 (es) Procedimiento de preparar nuevas bencensulfonil-lactamas
PL344056A1 (en) Piperididinyl and n-amidinopiperidinyl derivatives
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
HU9200335D0 (en) Medical products with human interleukin-2 content
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
PT1250291E (pt) Agente de melhoramento da agua contendo algas coralinas
GB2362103B (en) Pharmaceutical compositions including alginates
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
SE0201837D0 (sv) Chemical compounds
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
HK1075656A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds